With the recent FDA approval of neoadjuvant chemotherapy and nivolumab for Stage IB-IIIA NSCLC, does the fact that the study used AJCC 7th edition staging impact your patient selection at all since we currently are using 8th edition staging?

2 Answers

Mednet Member

Medical Oncology · Wexner Medical Center at The Ohio State University

No. The regimen is approved for all tumors greater than 4 cm OR node positive, and broad benefit was observed in all clinical categories.

Mednet Member

Medical Oncology · Cancer Care of Western Arizona

No.

With the recent FDA approval of neoadjuvant chemotherapy and nivolumab for Stage IB-IIIA NSCLC, does the fact that the study used AJCC 7th edition staging impact your patient selection at all since we currently are using 8th edition staging? | Mednet